S036 A New Paradigm in the Management of the Hidradenitis Suppurativa Disease Spectrum
DESCRIPTION
This session will provide dermatologists with a complete framework with end-to-end practical decision-making ability to manage patients with HS across the spectrum of disease, inclusive of medical and procedure-based strategies. Discussion of novel concepts in the management of HS supporting this framework will include the following as examples: defining early moderate disease which determines real-world eligibility for targeted treatments; assessing adequacy of initial treatment approach and timing of treatment switches; evaluating for disease progression and remission; choosing off-label strategies having proof of concept to manage recalcitrant disease; and deploying office based procedures to improve symptom control and outcomes.
LEARNING OBJECTIVES
Classify patients with early moderate disease to determine optimal treatment strategy and timing
Describe a practical framework to assess initial treatment adequacy, disease progression, as well as the need and timing to modify therapy
Design a management strategy that incorporates advanced medical therapies, office-based procedures, or sound off-label strategies for progressive or recalcitrant disease
SCHEDULE
1:00 PM
Discussion
DIRECTOR
Amit Garg, MD, FAAD
Northwell Health
SPEAKERS
Falk Bechara
Falk G. Bechara, Department of Dermatology, Venereology and Allergology, International Center for Hidradenitis Suppurativa/Acne Inversa (ICH), Ruhr-University Bochum; Germany
John Frew, MBBS, IFAAD
University of New South Wales, Sydney, Australia
Jennifer Lin Hsiao, MD, FAAD
Keck School of Medicine, University of Southern California
John Ingram, PhD, MD
Joslyn S. Kirby, MD, FAAD
Penn State Health
DISCLOSURES
Falk Bechara
AbbVie – Advisory Board(Fees); Acelyrin – Other(Fees); Almirall – Other(Fees); Avalo – Other(Fees); Boehringer Ingelheim – Other(Fees); Celltrion – Advisory Board(Fees); Citryll – Other(Fees); Incyte – Other(Fees); Janssen-Cilag – Speaker(Fees); Mölnlycke – Other(Fees); MoonLake Immunotherapeutics – Advisory Board(Fees); Navigator Medicines – Other(Fees); NewBridge Pharmaceuticals – Speaker(Fees); Novartis – Speaker(Fees); Sanofi – Other(Fees); Sitala Bio Ltd – Other(Fees); UCB Pharma – Speaker(Fees);
John Frew, MBBS, IFAAD
Abbvie – Advisory Board(Honoraria); Amgen – Speaker(Honoraria); Apogee – Advisory Board(Honoraria); Avalo Therapeutics Inc – Advisory Board(Honoraria); Behringer-Ingelheim – Advisory Board(Honoraria); Bristol-Myers Squibb – Investigator(Grants/Research Funding); Elasmogen – Advisory Board(Honoraria); JNJ – Advisory Board(Honoraria); Leo Pharma – Advisory Board(Honoraria); MoonLake Immunotherapeutics – Advisory Board(Honoraria); Novartis – Advisory Board(Honoraria); Regeneron – Advisory Board(Honoraria);
Amit Garg, MD, FAAD
AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Bluefin Biomedicine – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Leo Pharma – Advisory Board(Honoraria); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Otsuka Pharmaceutical Co., Ltd. – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);
Jennifer Lin Hsiao, MD, FAAD
AbbVie – Consultant(Fees), Speaker(Fees); Aclaris Therapeutics Inc. – Consultant (1099 relationship)(Fees); Amgen – Investigator(Grants/Research Funding); Astra Zeneca – Investigator(Grants/Research Funding); Avalo – Consultant (1099 relationship)(Fees); Boehringer Ingelheim – Consultant(Fees), Investigator(Grants/Research Funding), Speaker(Fees); Galderma – Speaker(Fees); Incyte – Consultant (1099 relationship)(Fees), Investigator(Grants/Research Funding); Insmed – Consultant (1099 relationship)(Fees); Leo Pharma – Consultant (1099 relationship)(Fees); Merck – Consultant (1099 relationship)(Fees); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Fees); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Fees), Speaker(Fees); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Pfizer Inc. – Consultant (1099 relationship)(Fees); Sanofi – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Speaker(Fees); Spyre Therapeutics – Consultant (1099 relationship)(Fees); UCB – Consultant(Fees), Speaker(Fees);
John Ingram, PhD, MD
AbbVie – Consultant(Honoraria); Bluefin Biomedicine – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant(Honoraria); British Journal of Dermatology – Other(Honoraria); Cantargia – Consultant (1099 relationship)(Honoraria); ChemoCentryx – Consultant(Honoraria); Citryll – Consultant(Honoraria); Elasmogen – Consultant (1099 relationship)(Honoraria); Engitix – Consultant (1099 relationship)(Honoraria); Incyte – Consultant (1099 relationship)(Honoraria); Indero, Inc. – Consultant (1099 relationship)(Honoraria); InflaRx – Consultant (1099 relationship)(Honoraria); Insmed Incorporated – Advisory Board(Honoraria); Kymera Therapeutics – Advisory Board(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); Novartis – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); UCB – Consultant(Honoraria); Union Therapeutics – Consultant (1099 relationship)(Honoraria); Viela Bio – Advisory Board(Honoraria);
Joslyn S. Kirby, MD, FAAD
Incyte Corporation – Consultant (1099 relationship)(Fees), Employee (w-2 relationship)(Salary); Penn State University – Other(Patent royalties or other compensation for Intellectual Property Rights);